Skip to content
Back to the Guavy Wire
Stocks

Merck Discontinues Nemtabrutinib Program Amid Promising Pipeline Growth

Instruments
MRK
Share

Merck (MRK) has made significant strides in advancing its pipeline, particularly in oncology, vaccines, and infectious diseases. The company's phase III pipeline has nearly tripled since 2021, driven by both in-house developments and strategic acquisitions. Merck aims to launch 20 new drugs by 2030, with several already showing blockbuster potential.

However, Merck recently faced a setback with the discontinuation of the BELLWAVE clinical development program for nemtabrutinib (MK-1026). This investigational oral Bruton's tyrosine kinase inhibitor was being developed for chronic lymphocytic leukemia and other hematologic malignancies. The decision followed a review by an external Data Monitoring Committee, which suggested that the potential benefits may not outweigh the risks.

Despite this setback, Merck's broader pipeline remains promising. Key late-stage candidates include sacituzumab tirumotecan (sac-TMT) for multiple tumor types, MK-8591D/islatravir plus lenacapavir for HIV, and alimatravir for HIV PrEP. The company is also advancing tulisokibart for immunology indications and intismeran autogene (V940), a personalized cancer therapy developed in collaboration with Moderna (MRNA).

Merck expects over $70 billion in potential non-risk-adjusted commercial opportunity for its current pipeline by the mid-2030s. This estimate is more than double the peak consensus sales estimate for Keytruda, which is set to expire in 2028. The company has also been active in acquisitions, adding Ohtuvayre, MK-1406, and MK-4208 to its portfolio.

Keytruda, Merck's blockbuster PD-1 inhibitor, faces competition from Bristol Myers' Opdivo, Roche's Tecentriq, and AstraZeneca's Imfinzi. Year to date, Merck's shares have rallied 39%, outperforming the industry's 28.1% rise. The stock is trading at a discount compared to the industry, with a forward price/earnings ratio of 17.19.

More on Stocks